DefNEtTrp: An Iron Dual Chelator Approach for Anticancer Application

Targeting iron metabolism has emerged as a novel therapeutic strategy for the treatment of cancer. As such, iron chelator drugs are repurposed or specifically designed as anticancer agents. Two important chelators, deferasirox (Def) and triapine (Trp), attack the intracellular supply of iron (Fe) an...

Full description

Saved in:

Bibliographic Details
Main Author:	Israel Rodríguez (9627988) (author)
Other Authors:	Carmen Acosta (16964183) (author), Christopher Nieves-Escobar (20381604) (author), Estelle Strangmark (20381607) (author), Oscar Claudio-Ares (20381610) (author), Adriana I. Vargas Figueroa (20381613) (author), Alexandra M. Soto-Millán (20381616) (author), Aixa M. Orta-Rivera (20381619) (author), Andrei V. Astashkin (1324170) (author), Arthur D. Tinoco (435324) (author)
Published:	2024
Subjects:	Biochemistry Cell Biology Pharmacology Biotechnology Cancer Chemical Sciences not elsewhere classified two important chelators tof mass spectrometry rnr ), responsible reduction potential (< novel therapeutic strategy dependent ribonucleotide reductase dependent pathways responsible cyclic voltammetry analyses cell death mechanism cell death behavior 77 ± 0 6 ± 0 high affinity fe trp ), attack defnettrp exhibits potent 50 </ sub redox active fe 1 ± 0 iron chelator drugs 2 </ sub e </ redox modulation dual chelator chelator moieties >< sub inhibit fe complex fe work aimed trp moieties trp ligands spectrum antiproliferative specifically designed recent efforts intracellular supply epr spectroscopy dna replication combination treatments cellular proliferation biological window anticancer therapy anticancer agents 15 μm 06 μm 04 μm
Tags:	Add Tag No Tags, Be the first to tag this record!

DefNEtTrp: An Iron Dual Chelator Approach for Anticancer Application

Similar Items